Test Bank for Urinalysis and Body Fluids 6th Edition by Strasinger

Original price was: $35.00.Current price is: $26.50.

Test Bank for Urinalysis and Body Fluids 6th Edition by Strasinger Digital Instant Download

Category:

This is completed downloadable of Test Bank for Urinalysis and Body Fluids 6th Edition by Strasinger

Product Details:

  • ISBN-10 ‏ : ‎ 9780803639201
  • ISBN-13 ‏ : ‎ 978-0803639201
  • Author:   Susan King Strasinger (author) & Marjorie Schaub Di Lorenzo (author) (Author)

Here’s a concise, comprehensive, and carefully structured introduction to the analysis of non-blood body fluids. Through six editions, the authors, noted educators and clinicians, have taught generations of students the theoretical and practical knowledge every clinical laboratory scientist needs to handle and analyze non-blood body fluids, and to keep themselves and their laboratories safe from infectious agents.

Their practical, focused, and reader friendly approach first presents the foundational concepts of renal function and urinalysis. Then, step by step, they focus on the examination of urine, cerebrospinal fluid, semen, synovial fluid, serous fluid, amniotic fluid, feces, and vaginal secretions.

The 6th Edition has been completely updated to include all of the new information and new testing procedures that are important in this rapidly changing field. Case studies, clinical situations, learning objectives, key terms, summary boxes, and study questions show how work in the classroom translates to work in the lab.

Redeem the Plus Code inside new, printed texts to access your DavisPlus student resources, including Davis Digital, your complete text online.

 

Table of Content:

  1. PART ONE Background
  2. CHAPTER 1 Safety and Quality Assessment
  3. LEARNING OBJECTIVES
  4. KEY TERMS
  5. SAFETY
  6. Biologic Hazards
  7. Table 1–1 Types of Safety Hazards
  8. Figure 1–1 Chain of infection and safety practices related to the biohazard symbol.
  9. Personal Protective Equipment
  10. Hand Hygiene
  11. PROCEDURE 1-1 Hand Washing Procedure
  12. Biologic Waste Disposal
  13. Sharp Hazards
  14. Figure 1–2 Biohazard symbol.
  15. Figure 1–3 Technologist disposing of urine (A) sample and (B) container.
  16. Chemical Hazards
  17. Chemical Spills and Exposure
  18. Chemical Handling
  19. Chemical Hygiene Plan
  20. Chemical Labeling
  21. Material Safety Data Sheets
  22. Figure 1–4 Chemical safety aids. A, emergency shower; B, eye wash station.
  23. Radioactive Hazards
  24. Electrical Hazards
  25. Figure 1–5 Chemical hazard symbols.
  26. Fire/Explosive Hazards
  27. Figure 1–6 NFPA hazardous material symbols.
  28. Physical Hazards
  29. Table 1–2 Types of Fires and Fire Extinguishers
  30. QUALITY ASSESSMENT
  31. Urinalysis Procedure Manual
  32. Preexamination Variables
  33. Figure 1–7 Example of procedure review documentation.
  34. Specimen Collection and Handling
  35. Figure 1–8 Cause-and-effect diagram for analyzing urinalysis TAT.
  36. Table 1–3 Policy for Handling Mislabeled Specimens
  37. Table 1–4 Criteria for Urine Specimen Rejection
  38. Examination Variables
  39. Reagents
  40. Instrumentation and Equipment
  41. Testing Procedure
  42. Quality Control
  43. Figure 1–9 Sample of Quality Improvement Follow-up Report form.
  44. Figure 1–10 Sample instrument QC recording sheet.
  45. External Quality Control
  46. Internal Quality Control
  47. Figure 1–11 Levy-Jennings charts showing in-control, shift, and trend results.
  48. Electronic Controls
  49. Proficiency Testing (External Quality Assessment)
  50. Personnel and Facilities
  51. Figure 1–12 “Out-of-control” procedures.
  52. Postexamination Variables
  53. Reporting Results
  54. Figure 1–13 Sample standardized urine microscopic reporting format.
  55. Figure 1–14 An example of procedure instructions for reporting critical values in the urinalysis section. A procedure review document similar to that shown in Figure 1–7 would accompany this instruction sheet.
  56. SUMMARY 1-1 Quality Assessment Errors
  57. Preexamination
  58. Examination
  59. Postexamination
  60. Interpreting Results
  61. References
  62. Study Questions
  63. Case Studies and Clinical Situations
  64. CHAPTER 2 Introduction to Urinalysis
  65. LEARNING OBJECTIVES
  66. KEY TERMS
  67. History and Importance
  68. Figure 2–1 Physician examines urine flask.
  69. Figure 2–2 Instruction in urine examination.
  70. Figure 2–3 A chart used for urine analysis.
  71. Urine Formation
  72. Urine Composition
  73. Urine Volume
  74. TECHNICAL TIP
  75. Table 2–1 Primary Components in Normal Urine3
  76. Figure 2–4 Differentiation between diabetes mellitus and diabetes insipidus.
  77. Specimen Collection
  78. Containers
  79. Labels
  80. Requisitions
  81. Specimen Rejection
  82. TECHNICAL TIP
  83. Table 2–2 Changes in Unpreserved Urine
  84. Specimen Handling
  85. Specimen Integrity
  86. Specimen Preservation
  87. TECHNICAL TIP
  88. TECHNICAL TIP
  89. Table 2–3 Urine Preservatives
  90. Types of Specimens
  91. Random Specimen
  92. Table 2–4 Types of Urine Specimens
  93. First Morning Specimen
  94. HISTORICAL NOTE
  95. Glucose Tolerance Specimens
  96. 24-Hour (or Timed) Specimen
  97. PROCEDURE 2-1 Sample 24-Hour (Timed) Specimen Collection Procedure
  98. TECHNICAL TIP
  99. Catheterized Specimen
  100. Midstream Clean-Catch Specimen
  101. Suprapubic Aspiration
  102. Prostatitis Specimen
  103. Three-Glass Collection
  104. TECHNICAL TIP
  105. PROCEDURE 2-2 Clean-Catch Specimen Collection: Female Cleansing Procedure2
  106. PROCEDURE 2-3 Clean-Catch Specimen Collection: Male Cleansing Procedure2
  107. Pre- and Post-Massage Test
  108. Pediatric Specimens
  109. HISTORICAL NOTE
  110. Stamey-Mears Test for Prostatitis
  111. TECHNICAL TIP
  112. Drug Specimen Collection
  113. PROCEDURE 2-4 Urine Drug Specimen Collection Procedure
  114. References
  115. Study Questions
  116. Case Studies and Clinical Situations
  117. CHAPTER 3 Renal Function
  118. LEARNING OBJECTIVES
  119. KEY TERMS
  120. Renal Physiology
  121. Figure 3–1 The relationship of the nephron to the kidney and excretory system.
  122. Renal Blood Flow
  123. Figure 3–2 The nephron and its component parts.
  124. Glomerular Filtration
  125. Cellular Structure of the Glomerulus
  126. Glomerular Pressure
  127. TECHNICAL TIP
  128. Figure 3–3 Factors affecting glomerular filtration in the renal corpuscle (A). Inset B, glomerular filtration barrier. Inset C, the shield of negativity.
  129. Renin-Angiotensin-Aldosterone System
  130. Figure 3–4 Close contact of the distal tubule with the afferent arteriole, macula densa, and the juxtaglomerular cells within the juxtaglomerular apparatus. Note the smaller size of the afferent arteriole indicating increased blood pressure.
  131. Figure 3–5 Algorithm of the renin-angiotensin-aldosterone system.
  132. Table 3–1 Actions of the RAAS
  133. Tubular Reabsorption
  134. Reabsorption Mechanisms
  135. Table 3–2 Tubular Reabsorption
  136. TECHNICAL TIP
  137. Tubular Concentration
  138. Collecting Duct Concentration
  139. Figure 3–6 Renal concentration.
  140. Tubular Secretion
  141. Figure 3–7 Summary of movement of substances in the nephron.
  142. Acid–Base Balance
  143. Figure 3–8 Reabsorption of filtered bicarbonate.
  144. Figure 3–9 Excretion of secreted hydrogen ions combined with phosphate.
  145. Figure 3–10 Excretion of secreted hydrogen ions combined with ammonia produced by the tubules.
  146. Renal Function Tests
  147. Figure 3–11 The relationship of nephron areas to renal function tests.
  148. Glomerular Filtration Tests
  149. Clearance Tests
  150. HISTORICAL NOTE
  151. Urea Clearance
  152. HISTORICAL NOTE
  153. Inulin Clearance
  154. Creatinine Clearance
  155. Procedure
  156. EXAMPLE
  157. EXAMPLE
  158. Estimated Glomerular Filtration Rates
  159. Figure 3–12 Creatinine filtration and excretion.
  160. Figure 3–13 A nomogram for determining body surface area.
  161. HISTORICAL NOTE
  162. Original MDRD Calculation
  163. Cystatin C
  164. Beta2-Microglobulin
  165. Radionucleotides
  166. Clinical Significance
  167. Tubular Reabsorption Tests
  168. Figure 3–14 The effect of hydration on renal concentration. Notice the decreased specific gravity in the more-hydrated Patient B.
  169. Osmolality
  170. Figure 3–15 Differentiation of neurogenic and nephrogenic diabetes insipidus.
  171. Freezing Point Osmometers
  172. Vapor Pressure Osmometers
  173. Technical Factors
  174. Clinical Significance
  175. TECHNICAL TIP
  176. Free Water Clearance
  177. EXAMPLE
  178. Tubular Secretion and Renal Blood Flow Tests
  179. PAH Test
  180. Titratable Acidity and Urinary Ammonia
  181. HISTORICAL NOTE
  182. Phenolsulfonphthalein Test
  183. References
  184. Study Questions
  185. Case Studies and Clinical Situations
  186. PART TWO Urinalysis
  187. CHAPTER 4 Physical Examination of Urine
  188. LEARNING OBJECTIVES
  189. KEY TERMS
  190. Color
  191. Table 4–1 Laboratory Correlation of Urine Color1
  192. Normal Urine Color
  193. Abnormal Urine Color
  194. Dark Yellow/Amber/Orange
  195. Red/Pink/Brown
  196. Brown/Black
  197. Figure 4–1 Differentiation of red urine testing chemically positive for blood.
  198. Blue/Green
  199. Clarity
  200. Normal Clarity
  201. Table 4–2 Urine Clarity
  202. PROCEDURE 4-1 Urine Color and Clarity Procedure
  203. Nonpathologic Turbidity
  204. Pathologic Turbidity
  205. Table 4–3 Nonpathologic Causes of Urine Turbidity
  206. Specific Gravity
  207. Table 4–4 Pathologic Causes of Urine Turbidity
  208. Refractometer
  209. Box 4-1 Current Urine Specific Gravity Measurements
  210. HISTORICAL NOTE
  211. Urinometry
  212. EXAMPLE
  213. Figure 4–2 Steps in the use of the urine specific gravity refractometer.
  214. Figure 4–3 Calibration of the urine specific gravity refractometer.
  215. Osmolality
  216. HISTORICAL NOTE
  217. Harmonic Oscillation Densitometry
  218. TECHNICAL TIP
  219. Table 4–5 Particle Changes to Colligative Properties
  220. Reagent Strip Specific Gravity
  221. Odor
  222. TECHNICAL TIP
  223. Table 4–6 Possible Causes of Urine Odor1
  224. References
  225. Study Questions
  226. Case Studies and Clinical Situations
  227. CHAPTER 5 Chemical Examination of Urine
  228. LEARNING OBJECTIVES
  229. KEY TERMS
  230. Reagent Strips
  231. Reagent Strip Technique
  232. Errors Caused by Improper Technique
  233. PROCEDURE 5-1 Reagent Strip Technique1,2
  234. Handling and Storing Reagent Strips
  235. Quality Control of Reagent Strips
  236. Confirmatory Testing
  237. pH
  238. Clinical Significance
  239. SUMMARY 5-1 Care of Reagent Strips
  240. Table 5–1 Causes of Acid and Alkaline Urine
  241. TECHNICAL TIP
  242. SUMMARY 5-2 Clinical Significance of Urine pH
  243. Reagent Strip Reactions
  244. TECHNICAL TIP
  245. SUMMARY 5-3 pH Reagent Strip
  246. Protein
  247. Clinical Significance
  248. Prerenal Proteinuria
  249. Bence Jones Protein
  250. Renal Proteinuria
  251. Glomerular Proteinuria
  252. Microalbuminuria
  253. HISTORICAL NOTE
  254. Screening Test for Bence Jones Protein
  255. Orthostatic (Postural) Proteinuria
  256. Tubular Proteinuria
  257. Postrenal Proteinuria
  258. HISTORICAL NOTE
  259. Microalbuminuria Testing
  260. Reagent Strip Reactions
  261. SUMMARY 5-4 Clinical Significance of Urine Protein
  262. Reaction Interference
  263. Sulfosalicylic Acid Precipitation Test
  264. Testing for Microalbuminuria
  265. TECHNICAL TIP
  266. SUMMARY 5-5 Clinical Significance of Urine Protein
  267. PROCEDURE 5-2 Sulfosalicylic Acid Precipitation Test
  268. Table Reporting SSA Turbidity
  269. Albumin: Creatinine Ratio
  270. Reagent Strip Reactions
  271. Albumin
  272. Creatinine
  273. Albumin/Protein: Creatinine Ratio
  274. Glucose
  275. Clinical Significance
  276. Figure 5–1 A protein:creatinine ratio determination chart.
  277. SUMMARY 5-6 Immunologic Tests
  278. SUMMARY 5-7 Clinical Significance of Urine Glucose
  279. Reagent Strip (Glucose Oxidase) Reaction
  280. Reaction Interference
  281. Copper Reduction Test (Clinitest)
  282. SUMMARY 5-8 Glucose Reagent Strip
  283. Clinical Significance of Clinitest
  284. PROCEDURE 5-3 Clinitest Procedure
  285. Ketones
  286. Clinical Significance
  287. TECHNICAL TIP
  288. SUMMARY 5-9 Clinical Significance of Urine Ketones
  289. Reagent Strip Reactions
  290. Reaction Interference
  291. Acetest Tablets
  292. Blood
  293. Figure 5–2 Production of acetone and butyrate from acetoacetic acid.
  294. PROCEDURE 5-4 Acetest Procedure
  295. Clinical Significance
  296. Hematuria
  297. Hemoglobinuria
  298. Myoglobinuria
  299. Reagent Strip Reactions
  300. SUMMARY 5-11 Clinical Significance of a Positive Reaction for Blood
  301. HISTORICAL NOTE
  302. Hemoglobinuria Versus Myoglobinuria
  303. Reaction Interference
  304. SUMMARY 5-12 Blood Reagent Strip
  305. Bilirubin
  306. Bilirubin Production
  307. Clinical Significance
  308. Table 5–2 Urine Bilirubin and Urobilinogen in Jaundice
  309. SUMMARY 5-13 Clinical Significance of Urine Bilirubin
  310. Figure 5–3 Hemoglobin degradation and production of bilirubin and urobilinogen.
  311. Reagent Strip (Diazo) Reactions
  312. Reaction Interference
  313. Ictotest Tablets
  314. SUMMARY 5-14 Bilirubin Reagent Strip
  315. PROCEDURE 5-5 Ictotest Procedure
  316. Urobilinogen
  317. Clinical Significance
  318. Reagent Strip Reactions and Interference
  319. SUMMARY 5-15 Clinical Significance of Urine Urobilinogen
  320. Reaction Interference
  321. Nitrite
  322. Clinical Significance
  323. TECHNICAL TIP
  324. SUMMARY 5-16 Urobilinogen Reagent Strip
  325. Reagent Strip Reactions
  326. Reaction Interference
  327. SUMMARY 5-17 Clinical Significance of Urine Nitrite
  328. SUMMARY 5-18 Nitrite Reagent Strip
  329. Leukocyte Esterase
  330. Clinical Significance
  331. Reagent Strip Reaction
  332. SUMMARY 5-19 Clinical Significance of Urine Leukocytes
  333. Reaction Interference
  334. Specific Gravity
  335. Reagent Strip Reaction
  336. SUMMARY 5-21 Clinical Significance of Urine Specific Gravity
  337. Figure 5–4 Diagram of reagent strip–specific gravity reaction.
  338. Reaction Interference
  339. SUMMARY 5-22 Urine Specific Gravity Reagent Strip
  340. References
  341. Study Questions
  342. Case Studies and Clinical Situations
  343. CHAPTER 6 Microscopic Examination of Urine
  344. LEARNING OBJECTIVES
  345. KEY TERMS
  346. Macroscopic Screening
  347. Table 6–1 Macroscopic Screening and Microscopic Correlations
  348. Specimen Preparation
  349. Specimen Volume
  350. Centrifugation
  351. Sediment Preparation
  352. Volume of Sediment Examined
  353. Commercial Systems
  354. Examining the Sediment
  355. Reporting the Microscopic Examination
  356. EXAMPLE
  357. Correlating Results
  358. HISTORICAL NOTE
  359. Addis Count
  360. Table 6–2 Routine Urinalysis Correlations
  361. Sediment Examination Techniques
  362. Sediment Stains
  363. Table 6–3 Urine Sediment Stain Characteristics
  364. Table 6–4 Expected Staining Reactions of Urine Sediment Constituents
  365. Lipid Stains
  366. Gram Stain
  367. Hansel Stain
  368. Prussian Blue Stain
  369. Cytodiagnostic Urine Testing
  370. Microscopy
  371. The Microscope
  372. Table 6–5 Urinalysis Microscopic Techniques
  373. Figure 6–1 Parts of the binocular microscope.
  374. PROCEDURE 6-1 Care of the Microscope
  375. Köhler Illumination
  376. Figure 6–2 Centering the condenser and Köhler illumination.
  377. Types of Microscopy
  378. Bright-Field Microscopy
  379. Phase-Contrast Microscopy
  380. Polarizing Microscopy
  381. Figure 6–3 Phase-contrast ring adjustment.
  382. Interference-Contrast Microscopy
  383. Figure 6–4 Diagram of polarized light.
  384. Dark-Field Microscopy
  385. Figure 6–5 Differential interference-contrast (Nomarski) microscopy.
  386. Fluorescence Microscopy
  387. Figure 6–6 Dark-field microscopy.
  388. Urine Sediment Constituents
  389. Red Blood Cells
  390. Figure 6–7 Fluorescent microscopy.
  391. Figure 6–8 Normal RBCs (×400).
  392. Figure 6–9 Microcytic and crenated RBCs (×100).
  393. Figure 6–10 Yeast. The presence of budding forms aid in distinguishing from RBCs (×400).
  394. Figure 6–11 KOVA-stained squamous epithelial cells and oil droplets (×400). Notice how the oil droplet (arrow) resembles an RBC.
  395. Figure 6–12 Air bubble. Notice no formed elements are in focus (×100).
  396. Clinical Significance
  397. Figure 6–13 Dysmorphic RBCs (×400). Notice the smaller size and fragmentation.
  398. White Blood Cells
  399. SUMMARY 6-1 Microscopic RBCs
  400. Figure 6–14 RBCs and one WBC (×400). Notice the larger size and granules in the WBC.
  401. Figure 6–15 WBCs. A. One segmented and one nonsegmented WBC (×400). B. Notice the multilobed nucleoli (×400).
  402. Eosinophils
  403. Figure 6–16 Glitter cells (×400). Observe the very noticeable granules.
  404. Figure 6–17 Hansel-stained eosinophils (×400).
  405. Mononuclear Cells
  406. Figure 6–18 WBCs with acetic acid nuclear enhancement. Notice the ameboid shape in some of the WBCs.
  407. Epithelial Cells
  408. SUMMARY 6-2 Microscopic WBCs
  409. Squamous Epithelial Cells
  410. Figure 6–19 Sediment-containing squamous, caudate transitional, and RTE cells (×400).
  411. Figure 6–20 A. Squamous epithelial cells identifiable under low power (×100). B. KOVA-stained squamous epithelial cells (×400). Compare the size of the nucleus with the RBCs in Figure 6–8.
  412. Figure 6–21 Phenazopyridine-stained sediment showing squamous epithelial cells and phenazopyridine crystals formed following refrigeration (×400).
  413. Figure 6–22 Clump of squamous epithelial cells (×400).
  414. Figure 6–23 Clump of squamous epithelial cells with folded forms (×400).
  415. Transitional Epithelial (Urothelial) Cells
  416. Figure 6–24 Transitional epithelial cells.
  417. Figure 6–25 KOVA-stained spherical transitional epithelial cells (×400).
  418. Figure 6–26 Caudate transitional epithelial cells (×400).
  419. Figure 6–27 Syncytia of transitional epithelial cells from catheterized specimen (×400).
  420. Renal Tubular Epithelial Cells
  421. Figure 6–28 RTE cell. Columnar proximal convoluted tubule cell with granules and attached fat globules (×400). N, nucleus.
  422. Figure 6–29 RTE cells. Oval distal convoluted tubule cells. Notice the eccentrically placed nuclei (×400).
  423. Figure 6–30 RTE cells, cuboidal from the collecting duct (×400).
  424. Figure 6–31 Fragment of RTE cells from the collecting duct under phase microscopy (×400).
  425. Clinical Significance
  426. Figure 6–32 Prussian blue–stained hemosiderin granules.
  427. Oval Fat Bodies
  428. Figure 6–33 Oval fat body (×400).
  429. Figure 6–34 Sudan III-stained oval fat body (×400).
  430. Figure 6–35 Oval fat body under bright-field (left) and polarized (right) microscopy. Notice the Maltese cross formation (arrow) (×400).
  431. Bacteria
  432. SUMMARY 6-3 Epithelial Cells
  433. Figure 6–36 A. Rod-shaped bacteria often seen in urinary tract infections. B. KOVA-stained bacteria and WBC (×400).
  434. Yeast
  435. Figure 6–37 A. Budding yeast B. Yeast showing mycelial forms (×400).
  436. Parasites
  437. Figure 6–38 Trichomonas vaginalis. Notice the flagella and undulating membrane.
  438. Spermatozoa
  439. Figure 6–39 Schistosoma haematobium ova (×300). Eggs are often contained in the last few drops of urine expelled from the bladder.
  440. Figure 6–40 A. Enterobius vermicularis ova (×100) B. Enterobius vermicularis ova (×400).
  441. Figure 6–41 Spermatozoa (×400).
  442. Mucus
  443. Casts
  444. Figure 6–42 A. Mucus threads (×400). B. Mucus clump (×400).
  445. SUMMARY 6-4 Miscellaneous Structures
  446. Cast Composition and Formation
  447. Hyaline Casts
  448. Figure 6–43 Hyaline casts under low power (×100).
  449. Figure 6–44 Hyaline cast (A) and amorphous urates (B) attached to mucus pseudocast (×100).
  450. Figure 6–45 A. Hyaline cast (×400). B. Hyaline cast under phase microscopy (×400).
  451. Figure 6–46 Convoluted hyaline cast (×400).
  452. RBC Casts
  453. Figure 6–47 Hyaline cast containing occasional granules (×400).
  454. Figure 6–48 RBC cast (×400).
  455. Figure 6–49 KOVA-stained RBC cast under phase microscopy (×400).
  456. Figure 6–50 Disintegrating RBC cast. Notice the presence of free RBCs (arrows) to confirm identification.
  457. Figure 6–51 Cast containing hemoglobin pigment. A comparison of RBCs (A) and yeast (B) also can be made (×400).
  458. Figure 6–52 Granular, dirty, brown cast (×400).
  459. WBC Casts
  460. Figure 6–53 WBC cast. Notice the free WBCs to aid in identification.
  461. Figure 6–54 KOVA-stained WBC cast (×400).
  462. Figure 6–55 Disintegrating WBC cast (×400).
  463. Bacterial Casts
  464. Figure 6–56 WBC clump. Notice the absence of a cast matrix.
  465. Epithelial Cell Casts
  466. Fatty Casts
  467. Figure 6–57 RTE cell cast (×400).
  468. Figure 6–58 A. KOVA-stained RTE cell cast (×400). B. KOVA-stained RTE cell cast under phase microscopy (×400).
  469. Figure 6–59 RTE cast with bilirubin-stained cells (×400).
  470. Mixed Cellular Casts
  471. Figure 6–60 Fatty cast showing adherence of fat droplets (arrows) to cast matrix (×400).
  472. Figure 6–61 Fatty cast (×400).
  473. Figure 6–62 Fatty cast under phase microscopy (×400).
  474. Granular Casts
  475. Figure 6–63 Finely granular cast (A) and uric acid crystals (B) (×400).
  476. Figure 6–64 Granular cast formed at a tubular bend (×400).
  477. Figure 6–65 Granular disintegrating cellular cast (×400).
  478. Figure 6–66 Coarsely granular cast (A), squamous epithelial cell (B), and mucus (C) (×400).
  479. Waxy Casts
  480. Figure 6–67 Granular cast degenerating into waxy cast (×400).
  481. Figure 6–68 KOVA-stained waxy casts (×100).
  482. Figure 6–69 KOVA-stained waxy casts (×200).
  483. Figure 6–70 KOVA-stained waxy cast (×400).
  484. Broad Casts
  485. Urinary Crystals
  486. Figure 6–71 KOVA-stained broad waxy cast (×400).
  487. Figure 6–72 Broad granular cast becoming waxy (×400).
  488. Figure 6–73 Broad bile-stained waxy cast (×400).
  489. Crystal Formation
  490. General Identification Techniques
  491. SUMMARY 6-5 Urine Casts
  492. Normal Crystals Seen in Acidic Urine
  493. Table 6–6 Major Characteristics of Normal Urinary Crystals
  494. Figure 6–74 Amorphous urates (×400).
  495. Figure 6–75 Amorphous urates attached to a fiber.
  496. Figure 6–76 Uric acid crystals (×400).
  497. Figure 6–77 Clump of uric acid crystals (×400). Notice the whetstone, not hexagonal, shape that differentiates uric acid crystals from cystine crystals.
  498. Figure 6–78 A. Uric acid crystals under polarized light (×100). B. Uric acid crystals under polarized light (×400).
  499. Figure 6–79 Classic dihydrate calcium oxalate crystals (×400).
  500. Figure 6–80 Classic dihydrate calcium oxalate crystals under phase microscopy (×400).
  501. Figure 6–81 Attached classic dihydrate calcium oxalate crystals (×400).
  502. Figure 6–82 Monohydrate calcium oxalate crystals (×400).
  503. Normal Crystals Seen in Alkaline Urine
  504. Figure 6–83 Amorphous phosphates (×400). Urine pH 7.0.
  505. Figure 6–84 Amorphous phosphates (×400).
  506. Figure 6–85 Triple phosphate crystal (×400).
  507. Figure 6–86 Triple phosphate crystals (arrow) and amorphous phosphates (×400).
  508. Figure 6–87 Calcium carbonate crystals (×400).
  509. Figure 6–88 Ammonium biurate crystals (×400). Notice the “thorny apple” appearance.
  510. Figure 6–89 Ammonium biurate crystals A. Ammonium biurate and triple phosphate crystals (×100). Note thorn (arrow). B. Ammonium biurate and triple phosphate crystals (×400).
  511. Figure 6–90 Ammonium biurate crystals (×400). Note thorns (arrow).
  512. Abnormal Urine Crystals
  513. Cystine Crystals
  514. Cholesterol Crystals
  515. Table 6–7 Major Characteristics of Abnormal Urinary Crystals
  516. Figure 6–91 Cystine crystals (×400).
  517. Radiographic Dye Crystals
  518. Crystals Associated With Liver Disorders
  519. Figure 6–92 Clump of cystine crystals (×400). Notice the hexagonal shape still visible.
  520. Figure 6–93 Cholesterol crystals. Notice the notched corners (×400).
  521. Figure 6–94 Cholesterol crystals under polarized light (×400).
  522. Figure 6–95 Tyrosine crystals in fine needle clumps (×400).
  523. Figure 6–96 Tyrosine crystals in rosette forms (×400).
  524. Figure 6–97 Leucine crystals (×400). Notice the concentric circles.
  525. Figure 6–98 Bilirubin crystals. Notice the classic bright yellow color (×400).
  526. Sulfonamide Crystals
  527. Ampicillin Crystals
  528. Figure 6–99 Sulfa crystals in rosette form (×400).
  529. Figure 6–100 Sulfa crystals, WBCs, and bacteria seen in UTI (×400).
  530. Figure 6–101 Ampicillin crystals. A. Nonrefrigerated ampicillin crystals. (×400). B. Ampicillin crystals after refrigeration (×400).
  531. Urinary Sediment Artifacts
  532. Figure 6–102 Starch granules. Notice the dimpled center (×400).
  533. Figure 6–103 Fecal material and oil artifacts (×400).
  534. Figure 6–104 Pollen grain. Notice the concentric circles (×400).
  535. Figure 6–105 Fiber and squamous epithelial cell (×400).
  536. Figure 6–106 Fiber under polarized light (×100).
  537. Figure 6–107 Diaper fiber resembling a cast. Notice the refractility (×400).
  538. Figure 6–108 Vegetable fiber resembling waxy cast (×400).
  539. References
  540. Study Questions
  541. Case Studies and Clinical Situations
  542. CHAPTER 7 Renal Disease
  543. LEARNING OBJECTIVES
  544. KEY TERMS
  545. Glomerular Disorders
  546. Glomerulonephritis
  547. Acute Poststreptococcal Glomerulonephritis
  548. Rapidly Progressive (Crescentic) Glomerulonephritis
  549. Goodpasture Syndrome
  550. Wegener Granulomatosis
  551. Henoch-Schönlein Purpura
  552. Membranous Glomerulonephritis
  553. Membranoproliferative Glomerulonephritis
  554. Chronic Glomerulonephritis
  555. Immunoglobulin A Nephropathy
  556. Nephrotic Syndrome
  557. Minimal Change Disease
  558. Focal Segmental Glomerulosclerosis
  559. Tubular Disorders
  560. Acute Tubular Necrosis
  561. Table 7–1 Laboratory Testing in Glomerular Disorders
  562. Table 7–2 Clinical Information Associated With Glomerular Disorders
  563. Hereditary and Metabolic Tubular Disorders
  564. Fanconi Syndrome
  565. Alport Syndrome
  566. Uromodulin-Associated Kidney Disease
  567. Diabetic Nephropathy
  568. Nephrogenic Diabetes Insipidus
  569. TECHNICAL TIP
  570. Renal Glycosuria
  571. Interstitial Disorders
  572. Table 7–3 Laboratory Testing in Metabolic and Hereditary Tubular Disorders
  573. Table 7–4 Clinical Information Associated With Metabolic and Tubular Disorders
  574. Acute Pyelonephritis
  575. Chronic Pyelonephritis
  576. TECHNICAL TIP
  577. Acute Interstitial Nephritis
  578. Renal Failure
  579. Table 7–5 Laboratory Results in Interstitial Disorders
  580. Table 7–6 Clinical Information Associated With Interstitial Disorders
  581. Table 7–7 Causes of Acute Renal Failure
  582. Renal Lithiasis
  583. References
  584. Study Questions
  585. Case Studies and Clinical Situations
  586. CHAPTER 8 Urine Screening for Metabolic Disorders
  587. LEARNING OBJECTIVES
  588. KEY TERMS
  589. Overflow Versus Renal Disorders
  590. Table 8–1 Abnormal Metabolic Constituents or Conditions Detected in the Routine Urinalysis
  591. Newborn Screening Tests
  592. Table 8–2 Major Disorders of Protein and Carbohydrate Metabolism Associated With Abnormal Urinary Constituents, Classified by Functional Defect
  593. Figure 8–1 Specimen collection form for MS/MS newborn screening test.
  594. Amino Acid Disorders
  595. Phenylalanine-Tyrosine Disorders
  596. Phenylketonuria
  597. Figure 8–2 Phenylalanine and tyrosine metabolic pathway including the normal pathway (blue), enzymes (yellow), and disorders caused by failure to inherit particular enzymes (green).
  598. Tyrosyluria
  599. PROCEDURE 8-1
  600. Melanuria
  601. PROCEDURE 8-2 Nitroso-Naphthol Test for Tyrosine
  602. Alkaptonuria
  603. TECHNICAL TIP
  604. TECHNICAL TIP
  605. PROCEDURE 8-3 Homogentisic Acid Test
  606. TECHNICAL TIP
  607. Branched-Chain Amino Acid Disorders
  608. Maple Syrup Urine Disease
  609. Figure 8–3 α-Alpha amino acid and branched chain amino acid structures. A. Structure of an α-amino acid. B. Structure of the branched chain amino acid leucine.
  610. Organic Acidemias
  611. Tryptophan Disorders
  612. PROCEDURE 8-4
  613. Indicanuria
  614. 5-Hydroxyindoleacetic Acid
  615. Figure 8–4 Tryptophan metabolism.
  616. Cystine Disorders
  617. PROCEDURE 8-5
  618. Cystinuria
  619. PROCEDURE 8-6 Silver Nitroprusside Test for Homocystine
  620. Cystinosis
  621. Homocystinuria
  622. Porphyrin Disorders
  623. PROCEDURE 8-7
  624. Figure 8–5 Pathway of heme formation, including normal pathway (green), enzymes (orange), and stages affected by the major disorders (yellow) of porphyrin metabolism.
  625. Table 8–3 Common Porphyrias
  626. HISTORICAL NOTE
  627. Vampires in Old Europe
  628. Mucopolysaccharide Disorders
  629. PROCEDURE 8-8 Watson-Schwartz Differentiation Test
  630. PROCEDURE 8-9 Watson-Schwartz reactions.
  631. PROCEDURE 8-10
  632. Purine Disorders
  633. Carbohydrate Disorders
  634. PROCEDURE 8-11
  635. TECHNICAL TIP
  636. References
  637. Study Questions
  638. Case Studies and Clinical Situations
  639. PART THREE Other Body Fluids
  640. CHAPTER 9 Cerebrospinal Fluid
  641. LEARNING OBJECTIVES
  642. KEY TERMS
  643. Formation and Physiology
  644. Figure 9–1 The layers of the meninges. A, the layers of the meninges in the brain. B, the layers of the meninges in the spinal cord.
  645. Specimen Collection and Handling
  646. Figure 9–2 The flow of CSF through the brain and spinal column.
  647. Appearance
  648. Figure 9–3 CSF specimen collection tubes.
  649. TECHNICAL TIP
  650. TECHNICAL TIP
  651. Figure 9–4 Tubes of CSF. Appearance left to right is normal, xanthochromic, hemolyzed, and cloudy.
  652. Traumatic Collection (Tap)
  653. Uneven Blood Distribution
  654. Table 9–1 Clinical Significance of CSF Appearance
  655. Clot Formation
  656. Xanthochromic Supernatant
  657. Cell Count
  658. Methodology
  659. Figure 9–5 Neubauer counting chamber depicting the nine large square counting areas.
  660. Calculating CSF Cell Counts
  661. EXAMPLE
  662. Total Cell Count
  663. WBC Count
  664. Quality Control of CSF and Other Body Fluid Cell Counts
  665. Differential Count on a CSF Specimen
  666. Cytocentrifugation
  667. Figure 9–6 Cytospin 3 cytocentrifuge specimen processing assembly
  668. CSF Cellular Constituents
  669. Table 9–2 Cytocentrifuge Recovery Chart7
  670. Figure 9–7 Normal lymphocytes. Some cytocentrifuge distortion of cytoplasm (x1000).
  671. Figure 9–8 Normal lymphocytes and monocytes (x500).
  672. Neutrophils
  673. Table 9–3 Predominant Cells Seen in CSF
  674. Figure 9–9 Neutrophils with cytoplasmic vacuoles resulting from cytocentrifugation (x500).
  675. Figure 9–10 Neutrophils with intracellular bacteria (x1000).
  676. Figure 9–11 Neutrophils with intracellular and extracellular bacteria (x1000).
  677. Figure 9–12 Neutrophils with pyknotic nuclei. Notice the cell with a single nucleus in the center (x1000).
  678. Figure 9–13 Nucleated RBCs seen with bone marrow contamination (x1000).
  679. Lymphocytes and Monocytes
  680. Figure 9–14 Bone marrow contamination (x1000). Notice the immature RBCs and granulocytes.
  681. Figure 9–15 Capillary and tissue fragments from a traumatic tap (x100).
  682. Figure 9–16 Broad spectrum of lymphocytes and monocytes in viral meningitis (x1000).
  683. Eosinophils
  684. Macrophages
  685. Nonpathologically Significant Cells
  686. Figure 9–17 Eosinophils (x1000). Notice cytocentrifuge distortion.
  687. Figure 9–18 Macrophages. Notice the large amount of cytoplasm and vacuoles (x500).
  688. Figure 9–19 Macrophages showing erythrophagocytosis (x500).
  689. Figure 9–20 Macrophage with RBC remnants (x500).
  690. Figure 9–21 Macrophage with aggregated hemosiderin granules (x500).
  691. Figure 9–22 Macrophage containing hemosiderin stained with Prussian blue (x250).
  692. Figure 9–23 Macrophage with coarse hemosiderin granules (x500).
  693. Figure 9–24 Macrophage containing hemosiderin and hematoidin crystals (x500).
  694. Figure 9–25 Macrophages with hemosiderin and hematoidin (x250). Notice the bright yellow color.
  695. Figure 9–26 Choroidal cells showing distinct cell borders and nuclear uniformity (x500).
  696. Figure 9–27 Ependymal cells. Notice the nucleoli and less distinct cell borders (x1000).
  697. Malignant Cells of Hematologic Origin
  698. Figure 9–28 Cluster of spindle-shaped cells (x500).
  699. Figure 9–29 Lymphoblasts from acute lymphocytic leukemia (x500).
  700. Figure 9–30 Myeloblasts from acute myelocytic leukemia (x500).
  701. Figure 9–31 Monoblasts and two lymphocytes (x1000). Notice the prominent nucleoli.
  702. Figure 9–32 Cleaved and noncleaved lymphoma cells (x1000).
  703. Figure 9–33 Lymphoma cells with nucleoli (x500).
  704. Malignant Cells of Nonhematologic Origin
  705. Figure 9–34 Burkitt lymphoma. Notice characteristic vacuoles (x500).
  706. Figure 9–35 Medulloblastoma (x1000). Notice cellular clustering, nuclear irregularities, and rosette formation.
  707. Chemistry Tests
  708. Cerebrospinal Protein
  709. Clinical Significance of Elevated Protein Values
  710. Methodology
  711. Protein Fractions
  712. Table 9–4 Clinical Causes of Abnormal CSF Protein Values*
  713. Electrophoresis and Immunophoretic Techniques
  714. Figure 9–36 Normal and abnormal oligoclonal banding.
  715. Myelin Basic Protein
  716. CSF Glucose
  717. CSF Lactate
  718. CSF Glutamine
  719. Microbiology Tests
  720. Table 9–5 CSF Chemistry Tests
  721. Gram Stain
  722. Table 9–6 Major Laboratory Results for Differential Diagnosis of Meningitis
  723. Figure 9–37 India ink preparation of C. neoformans (x400). Notice budding yeast form.
  724. Figure 9–38 Gram stain of C. neoformans showing starburst pattern (x1000).
  725. Serologic Testing
  726. Figure 9–39 Naegleria fowleri trophozoite.
  727. References
  728. Study Questions
  729. Case Studies and Clinical Situations
  730. CHAPTER 10 Semen
  731. LEARNING OBJECTIVES
  732. KEY TERMS
  733. Physiology
  734. Table 10–1 Semen Composition
  735. Figure 10–1 The male genitalia. Top, sagittal view; bottom, anterior view.
  736. Specimen Collection
  737. SUMMARY 10-1 Semen Production
  738. TECHNICAL TIP
  739. Specimen Handling
  740. Semen Analysis
  741. Appearance
  742. Table 10–2 Reference Values for Semen Analysis5
  743. Liquefaction
  744. Volume
  745. Viscosity
  746. PROCEDURE 10-1
  747. PROCEDURE 10-2
  748. TECHNICAL TIP
  749. pH
  750. Sperm Concentration and Sperm Count
  751. Figure 10–2 Areas of the Neubauer counting chamber used for red and white blood cell counts. W, typical WBC counting area; R, typical RBC counting area.
  752. Calculating Sperm Concentration and Sperm Count
  753. EXAMPLES
  754. Sperm Motility
  755. Table 10–3 Sperm Motility Grading
  756. Table 10–4 Alternative Sperm Motility Grading Criteria1
  757. Sperm Morphology
  758. TECHNICAL TIP
  759. Figure 10–3 Normal spermatozoon structure.
  760. Figure 10–4 Spermatozoon with double head, hematoxylin-eosin (×1000).
  761. Figure 10–5 Spermatozoon with amorphous head, hematoxylin-eosin (×1000).
  762. Figure 10–6 Spermatozoon with double tail, hematoxylin-eosin (×1000).
  763. Calculating Round Cells
  764. Additional Testing
  765. Figure 10–7 Common abnormalities of sperm heads and tails.
  766. Figure 10–8 Spermatozoon with bent neck and spermatid, hematoxylin-eosin (×1000).
  767. Figure 10–9 Immature spermatozoa, hematoxylin-eosin (×1000).
  768. Sperm Vitality
  769. Seminal Fluid Fructose
  770. Table 10–5 Additional Testing for Abnormal Semen Analysis
  771. Figure 10–10 Nonviable spermatozoa demonstrated by the eosin-nigrosin stain (×1000).
  772. PROCEDURE 10-3
  773. Antisperm Antibodies
  774. Microbial and Chemical Testing
  775. Table 10–6 Reference Semen Chemical Values1
  776. Postvasectomy Semen Analysis
  777. Sperm Function Tests
  778. Semen Analysis Quality Control
  779. TECHNICAL TIP
  780. Table 10–7 Sperm Function Tests
  781. References
  782. Study Questions
  783. Case Studies and Clinical Situations
  784. CHAPTER 11 Synovial Fluid
  785. LEARNING OBJECTIVES
  786. KEY TERMS
  787. Physiology
  788. Figure 11–1 A synovial joint.
  789. Table 11–1 Normal Synovial Fluid Values2
  790. Specimen Collection and Handling
  791. Table 11–2 Classification and Pathologic Significance of Joint Disorders
  792. Table 11–3 Laboratory Findings in Joint Disorders3
  793. Table 11–4 Required Tube Types for Synovial Fluid Tests
  794. TECHNICAL TIP
  795. Color and Clarity
  796. Viscosity
  797. Cell Counts
  798. Differential Count
  799. Table 11–5 Cells and Inclusions Seen in Synovial Fluid
  800. Crystal Identification
  801. Types of Crystals
  802. Table 11–6 Characteristics of Synovial Fluid Crystals
  803. Slide Preparation
  804. Crystal Polarization
  805. Figure 11–2 Unstained wet prep of MSU crystals (×400). Notice the characteristic yellow-brown of the urate crystals.
  806. Figure 11–3 Wright’s-stained neutrophils containing CPPD crystals (×1000).
  807. Figure 11–4 Strongly birefringent MSU crystals under polarized light (×500).
  808. Figure 11–5 Weakly birefringent CPPD crystals under polarized light (×1000).
  809. Figure 11–6 Extracellular MSU crystals under compensated polarized light. Notice the change in color with crystal alignment (×100).
  810. Figure 11–7 MSU crystals under compensated polarized light. The yellow crystal is aligned with the slow vibration (×500).
  811. Figure 11–8 CPPD crystals under compensated polarized light. The blue crystal is aligned with the slow vibration (×1000).
  812. Chemistry Tests
  813. Figure 11–9 Negative and positive birefringence in MSU and CPPD crystals. (A) MSU crystal with grain running parallel to the long axis. The slow ray passes with the grain, producing negative (yellow) birefringence. (B) CPPD crystal with grain running perpendicular to the long axis. The slow ray passes against the grain and is retarded, producing positive (blue) birefringence.
  814. TECHNICAL TIP
  815. Microbiologic Tests
  816. Serologic Tests
  817. References
  818. Study Questions
  819. Case Studies and Clinical Situations
  820. CHAPTER 12 Serous Fluid
  821. LEARNING OBJECTIVES
  822. KEY TERMS
  823. Formation
  824. Specimen Collection and Handling
  825. Figure 12–1 The body areas and membranes where serous fluid is produced.
  826. Figure 12–2 The normal formation and absorption of pleural fluid.
  827. Table 12–1 Pathologic Causes of Effusions
  828. Transudates and Exudates
  829. General Laboratory Procedures
  830. Table 12–2 Laboratory Differentiation of Transudates and Exudates
  831. Pleural Fluid
  832. Appearance
  833. Table 12–3 Correlation of Pleural Fluid Appearance and Disease5
  834. Hematology Tests
  835. Table 12–4 Differentiation Between Chylous and Pseudochylous Pleural Effusions
  836. Table 12–5 Significance of Cells Seen in Pleural Fluid
  837. Figure 12–3 Systemic lupus erythematosus cell in pleural fluid. Notice the ingested “round body” (×1000).
  838. Figure 12–4 Normal pleural fluid mesothelial cells, lymphocytes, and monocytes (×250).
  839. Figure 12–5 Normal mesothelial cell (×500).
  840. Figure 12–6 Reactive mesothelial cells showing eccentric nuclei and vacuolated cytoplasm (×500).
  841. Figure 12–7 One normal and two reactive mesothelial cells with a multinucleated form (×500).
  842. Figure 12–8 Pleural fluid plasma cells seen in a case of tuberculosis. Notice the absence of mesothelial cells (×1000).
  843. Figure 12–9 Pleural fluid adenocarcinoma showing cytoplasmic molding (×250).
  844. Figure 12–10 Pleural fluid adenocarcinoma showing nuclear and cytoplasmic molding and vacuolated cytoplasm (×1000).
  845. Figure 12–11 Enhancement of nuclear irregularities using a toluidine blue stain (×250).
  846. Figure 12–12 Poorly differentiated pleural fluid adenocarcinoma showing nuclear irregularities and cytoplasmic vacuoles (×500).
  847. Figure 12–13 Pleural fluid small cell carcinoma showing nuclear molding (×250).
  848. Chemistry Tests
  849. Figure 12–14 Metastatic breast carcinoma cells in pleural fluid. Notice the hyperchromatic nucleoli (×1000).
  850. Table 12–6 Characteristics of Malignant Cells
  851. Table 12–7 Significance of Chemical Testing of Pleural Fluid
  852. Microbiologic and Serologic Tests
  853. Pericardial Fluid
  854. Figure 12–15 Algorithm of pleural fluid testing.
  855. Table 12–8 Significance of Pericardial Fluid Testing
  856. Appearance
  857. Laboratory Tests
  858. Figure 12–16 Malignant pericardial effusion showing giant mesothelioma cell with cytoplasmic molding and hyperchromatic nucleoli (×1000).
  859. Peritoneal Fluid
  860. Transudates Versus Exudates
  861. Table 12–9 Significance of Peritoneal Fluid Testing
  862. EXAMPLE
  863. Appearance
  864. Laboratory Tests
  865. Cellular Examination
  866. Figure 12–17 Lipophages (macrophages containing fat droplets) in peritoneal fluid (×500).
  867. Figure 12–18 Budding yeast in peritoneal fluid (×400).
  868. Figure 12–19 Ovarian carcinoma showing community borders, nuclear irregularity, and hyperchromatic nucleoli (×500).
  869. Figure 12–20 Ovarian carcinoma cells with large mucin-containing vacuoles (×500).
  870. Figure 12–21 Adenocarcinoma of the prostate showing cytoplasmic vacuoles, community borders, and hyperchromatic nucleoli (×500).
  871. Figure 12–22 Colon carcinoma cells containing mucin vacuoles and nuclear irregularities (×400).
  872. Figure 12–23 Psammoma bodies exhibiting concentric striations (×500).
  873. Chemical Testing
  874. Microbiology Tests
  875. Serologic Tests
  876. References
  877. Study Questions
  878. Case Studies and Clinical Situations
  879. CHAPTER 13 Amniotic Fluid
  880. LEARNING OBJECTIVES
  881. KEY TERMS
  882. Physiology
  883. Function
  884. Volume
  885. Table 13–1 Tests for Fetal Well-Being and Maturity
  886. Figure 13–1 Fetus in amniotic sac.
  887. Chemical Composition
  888. Differentiating Maternal Urine From Amniotic Fluid
  889. Specimen Collection
  890. Indications for Amniocentesis
  891. Table 13–2 Indications for Performing Amniocentesis
  892. Collection
  893. Specimen Handling and Processing
  894. Color and Appearance
  895. Tests for Fetal Distress
  896. Hemolytic Disease of the Newborn
  897. Table 13–3 Amniotic Fluid Color
  898. Figure 13–2 Rh antibodies crossing the placenta.
  899. Figure 13–3 Spectrophotometric bilirubin scan showing bilirubin and oxyhemoglobin peaks.
  900. Neural Tube Defects
  901. Figure 13–4 Example of a Liley graph.
  902. Tests for Fetal Maturity
  903. Fetal Lung Maturity
  904. Lecithin-Sphingomyelin Ratio
  905. Phosphatidyl Glycerol
  906. Foam Stability Index
  907. Lamellar Bodies
  908. PROCEDURE 13-1 Foam Shake Test
  909. PROCEDURE 13-2 Foam Stability Index
  910. HISTORICAL NOTE
  911. Microviscosity: Fluorescence Polarization Assay
  912. Lamellar Body Count
  913. PROCEDURE 13-3 Lamellar Body Count18
  914. References
  915. Study Questions
  916. Case Studies and Clinical Situations
  917. CHAPTER 14 Fecal Analysis
  918. LEARNING OBJECTIVES
  919. KEY TERMS
  920. Physiology
  921. Figure 14–1 Fluid regulation in the gastrointestinal tract.
  922. Diarrhea and Steatorrhea
  923. Diarrhea
  924. Secretory Diarrhea
  925. TECHNICAL TIP
  926. Osmotic Diarrhea
  927. Table 14–1 Common Fecal Tests for Diarrhea
  928. Table 14–2 Differential Features for Diarrhea
  929. Altered Motility
  930. Steatorrhea
  931. Specimen Collection
  932. Macroscopic Screening
  933. Color
  934. Appearance
  935. Table 14–3 Macroscopic Stool Characteristics12,26
  936. Microscopic Examination of Feces
  937. Fecal Leukocytes
  938. Muscle Fibers
  939. PROCEDURE 14-1 Methylene Blue Stain for Fecal Leukocytes
  940. Qualitative Fecal Fats
  941. Figure 14–2 Meat fibers present in fecal emulsion specimen using brightfield microscopy examination (×400).
  942. Figure 14–3 Note striations on meat fiber present in a fecal emulsion specimen (×1000).
  943. PROCEDURE 14-2 Muscle Fibers
  944. Figure 14–4 Several orange-red neutral fat globules present in a fecal suspension stained with Sudan III (×400).
  945. PROCEDURE 14-3 Neutral Fat Stain
  946. PROCEDURE 14-4 Split Fat Stain
  947. Chemical Testing of Feces
  948. Occult Blood
  949. Guaiac-Based Fecal Occult Blood Tests
  950. Immunochemical Fecal Occult Blood Test
  951. Porphyrin-Based Fecal Occult Blood Test
  952. Quantitative Fecal Fat Testing
  953. TECHNICAL TIP
  954. SUMMARY 14-1 gFOBT Interference
  955. False-Positive
  956. False-Negative
  957. PROCEDURE 14-5 Acid Steatocrit
  958. APT Test (Fetal Hemoglobin)
  959. Table 14–4 Tests, Materials, and Instrumentation for Fecal Fat Analysis19
  960. PROCEDURE 14-6 APT Test
  961. Fecal Enzymes
  962. HISTORICAL NOTE
  963. Screening Test for Fecal Trypsin
  964. Carbohydrates
  965. Table 14–5 Fecal Screening Tests
  966. References
  967. Study Questions
  968. Case Studies and Clinical Situations
  969. CHAPTER 15 Vaginal Secretions
  970. LEARNING OBJECTIVES
  971. KEY TERMS
  972. Specimen Collection and Handling
  973. Table 15–1 Clinical Features and Laboratory Findings in Vaginitis2
  974. Color and Appearance
  975. Diagnostic Tests
  976. pH
  977. Table 15–2 Normal Findings in Vaginal Secretions
  978. Microscopic Procedures
  979. PROCEDURE 15-1 pH Test
  980. Wet Mount Examination
  981. Squamous Epithelial Cells
  982. Table 15–3 Quantitation Scheme for Microscopic Examinations2
  983. Figure 15–1 Squamous epithelial cells identifiable under low power (×100).
  984. Clue Cells
  985. White Blood Cells
  986. Figure 15–2 Clump of squamous epithelial cells (×400).
  987. Figure 15–3 Clue cells (×400).
  988. Figure 15–4 White blood cells. Notice the multilobed nucleoli (×400).
  989. Red Blood Cells
  990. Parabasal Cells
  991. Figure 15–5 Normal red blood cells (×400).
  992. Figure 15–6 Parabasal cell surrounded by epithelial cells (×400).
  993. Basal Cells
  994. Bacteria
  995. Trichomonas vaginalis
  996. Figure 15–7 Bacteria. A, Large rods characteristic of Lactobacilli, the predominant bacteria in normal vaginal secretions (×400). B, Bacteria with white blood cells (×400).
  997. Yeast Cells
  998. Figure 15–8 Trichomonas vaginalis.
  999. Figure 15–9 Trichomonas vaginalis in wet mount.
  1000. KOH Preparation and Amine Test
  1001. Figure 15–10 Budding yeast cells (×400).
  1002. Figure 15–11 Yeast cells showing mycelial forms (×400).
  1003. Other Diagnostic Tests
  1004. Gram Stain
  1005. PROCEDURE 15-2 Saline Wet Mount2
  1006. PROCEDURE 15-3 KOH Preparation2
  1007. PROCEDURE 15-4 Amine (Whiff) Test
  1008. Table 15–4 Nugent’s Gram Stain Criteria to Diagnose Bacterial Vaginosis
  1009. Culture
  1010. DNA Testing
  1011. Point of Care Tests
  1012. Vaginal Disorders
  1013. Bacterial Vaginosis
  1014. Trichomoniasis
  1015. Candidiasis
  1016. Desquamative Inflammatory Vaginitis
  1017. Atrophic Vaginitis
  1018. Additional Vaginal Secretion Procedures
  1019. Fetal Fibronectin Test
  1020. AmniSure Test
  1021. References
  1022. Study Questions
  1023. Case Studies and Clinical Situations
  1024. Back Matter
  1025. APPENDIX A Urine and Body Fluid Analysis Automation
  1026. Urinalysis Automation
  1027. Table A–1 Measurement Technology Methods in Automated Urinalysis
  1028. Semi-Automated Urine Chemistry Analyzers
  1029. Table A–2 Urinalysis Automation
  1030. Fully Automated Urine Chemistry Analyzers
  1031. Figure A–1 DiaScreen50 semi-automated urine chemistry analyzer.
  1032. Figure A–2 Cobas u 411 urine chemistry analyzer.
  1033. Figure A–3 Urisys 1100 semi-automated urine chemistry analyzer.
  1034. Figure A–4 Clintek Status + Analyzer. A, Clinitek Status Connect with Barcode Stand. B, Clinitek Status with test strip.
  1035. Figure A–5 Clinitek Advantus semi-automated urine chemistry analyzer.
  1036. Figure A–6 iChem 100 semi-automated urine chemistry analyzer.
  1037. Automated Microscopy
  1038. Figure A–7 Urisys 2400 automated urine chemistry analyzer.
  1039. Figure A–8 Clinitek Atlas automated urine chemistry analyzer.
  1040. Sysmex UF-1000i
  1041. Figure A–9 Aution Max AX-4030 fully automated urine chemistry analyzer.
  1042. Figure A–10 iChem Velocity automated urine chemistry analyzer.
  1043. Figure A–11 Sysmex UF 1000i urine chemistry analyzer.
  1044. Figure A–12 Diagram of urine particle analysis in the Sysmex UF1000i.
  1045. Figure A–13 Staining elements for the Sysmex UF1000i.
  1046. Figure A–14 UF1000i signal waveform for cells.
  1047. iQ 200
  1048. Figure A–15 Scattergram showing Sysmex UF1000i microscopy results.
  1049. Figure A–16 iQ 200 microscopy analyzer.
  1050. Figure A–17 Diagram of the iQ 200 digital flow capture process.
  1051. Figure A–18 Auto-Particle Recognition (APR) process.
  1052. Figure A–19 iQ 200 urinalysis results display, showing particle categories available for analysis or counting.
  1053. Automated Urinalysis Systems
  1054. Figure A–20 AUWi, a fully automated urinalysis system that combines the Siemens Clinitek Atlas Chemistry analyzer and the Sysmex UF-1000i particle analyzer.
  1055. Figure A–21 iRICELL3000, a fully automated Urinalysis System that combines the iChem Velocity urine chemistry analyzer and the iQ 200 microscopy analyzer.
  1056. Body Fluid Analysis Automation
  1057. References
  1058. Additional Information Sources
  1059. APPENDIX B Bronchoalveolar Lavage
  1060. White and Red Blood Cell Counts
  1061. Leukocytes
  1062. Figure B–1 Bronchoalveolar lavage: Normal macrophages and lymphocytes (×1000).
  1063. Erythrocytes
  1064. Epithelial Cells
  1065. Figure B–2 Bronchoalveolar lavage: Ciliated bronchial epithelial cells; notice the eosinophilic bar (×1000).
  1066. Fungi, Viruses, and Bacteria
  1067. Figure B–3 Bronchoalveolar lavage: Amorphous material associated with P. carinii when examined under low power (×100).
  1068. Figure B–4 Bronchoalveolar lavage: Characteristic cup-shaped organisms indicating P. carinii (×1000).
  1069. Cytology
  1070. References
  1071. Answers to Study Questions and Case Studies and Clinical Situations
  1072. Chapter 1
  1073. Study Questions
  1074. Case Studies and Clinical Situations
  1075. Chapter 2
  1076. Study Questions
  1077. Case Studies and Clinical Situations
  1078. Chapter 3
  1079. Study Questions
  1080. Case Studies and Clinical Situations
  1081. Chapter 4
  1082. Study Questions
  1083. Case Studies and Clinical Situations
  1084. Chapter 5
  1085. Study Questions
  1086. Case Studies and Clinical Situations
  1087. Chapter 6
  1088. Study Questions
  1089. Case Studies and Clinical Situations
  1090. Chapter 7
  1091. Study Questions
  1092. Case Studies and Clinical Situations
  1093. Chapter 8
  1094. Study Questions
  1095. Case Studies and Clinical Situations
  1096. Chapter 9
  1097. Study Questions
  1098. Case Studies and Clinical Situations
  1099. Chapter 10
  1100. Study Questions
  1101. Case Studies and Clinical Situations
  1102. Chapter 11
  1103. Study Questions
  1104. Case Studies and Clinical Situations
  1105. Chapter 12
  1106. Study Questions
  1107. Case Studies and Clinical Situations
  1108. Chapter 13
  1109. Study Questions
  1110. Case Studies and Clinical Situations
  1111. Chapter 14
  1112. Study Questions
  1113. Case Studies and Clinical Situations
  1114. Chapter 15
  1115. Study Questions
  1116. Case Studies and Clinical Situations
  1117. Abbreviations
  1118. Glossary
  1119. Index